-
Posted by
Two Blokes Jul 12 -
Filed in
Stock
-
7 views
SelectQuote is undervalued at current levels, offering a compelling buying opportunity despite recent volatility and a disappointing Q3. Key catalysts include higher Medicare Advantage reimbursement rates, growing recurring revenue from SelectRx, and operational improvements boosting efficiency and margins. The company's valuation is attractive at less than 6x forward adjusted EBITDA, with confirmed growth drivers for both revenue and profitability in FY25 and beyond.
